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Abstract
Background
In primary and secondary care medically unexplained symptoms (MUS) or functional
somatic syndromes (FSS) constitute a major burden for patients and society with high
healthcare costs and societal costs. Objectives were to provide an overview of the evidence
regarding the cost-effectiveness of interventions for MUS or FSS, and to assess the quality
of these studies.
Methods
We searched the databases PubMed, PsycINFO, the National Health Service Economic
Evaluation Database (NHS-EED) and the CEA registry to conduct a systematic review.
Articles with full economic evaluations on interventions focusing on adult patients with undif-
ferentiated MUS or fibromyalgia (FM), irritable bowel syndrome (IBS) and chronic fatigue
syndrome (CFS), with no restrictions on comparators, published until 15 June 2018, were
included. We excluded preventive interventions. Two reviewers independently extracted
study characteristics and cost-effectiveness data and used the Consensus on Health Eco-
nomic Criteria Checklist to appraise the methodological quality.
Results
A total of 39 studies out of 1,613 articles met the inclusion criteria. Twenty-two studies
reported costs per quality-adjusted life year (QALY) gained and cost-utility analyses
(CUAs). In 13 CUAs the intervention conditions dominated the control conditions or had an
incremental cost-effectiveness ratio below the willingness-to-pay threshold of € 50,000 per
QALY, meaning that the interventions were (on average) cost-effective in comparison with
the control condition. Group interventions focusing on MUS (n = 3) or FM (n = 4) might be
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more cost-effective than individual interventions. The included studies were heterogeneous
with regard to the included patients, interventions, study design, and outcomes.
Conclusion
This review provides an overview of 39 included studies of interventions for patients with
MUS and FSS and the methodological quality of these studies. Considering the limited com-
parability due to the heterogeneity of the studies, group interventions might be more cost-
effective than individual interventions.
Registration
Study methods were documented in an international prospective register of systematic
reviews (PROSPERO) protocol, registration number: CRD42017060424.
Introduction
Patients with medically unexplained symptoms (MUS, i.e. physical symptoms for which no
pathological cause can be found after adequate physical examination) are highly prevalent in
primary and secondary care in all medical settings [1,2]. The classification of these physical
symptoms is problematic as numerous overlapping diagnoses and syndrome labels show
[3]. Almost each medical specialty has defined its own syndrome(s) based on symptoms that
relate to their organ of interest [4]. Psychiatry uses the designation somatic symptom disorder,
while most medical specialties have patients with clusters of MUS within so called ‘functional
somatic syndromes’ (FSS) [1] e.g. fibromyalgia (FM) [5], irritable bowel syndrome (IBS) [6],
chronic fatigue syndrome (CFS) [7], chronic benign pain syndrome and multiple chemical
sensitivity (MCS) [4,8]. The most well-known FSS are FM, IBS, and CFS [9] and most primary
care physicians and researchers are familiar with the umbrella term MUS [10].
MUS are often accompanied by psychological distress, social isolation and reduced quality
of life [11,12]. Severe MUS are associated with multiple functional impairments and psychiat-
ric morbidity [13–15]. Patients with MUS and FSS suffer from their symptoms, are function-
ally impaired [9] and are at risk for false-positive diagnostic tests, potentially harmful
additional testing and treatment procedures [16]. Therefore, these symptoms constitute a
major burden on patients and society with considerable societal costs, health care costs and
costs of lost productivity [9]. In a Dutch study (2005–2008) the mean total cost, both the use of
healthcare services (direct costs) and productivity-related costs (indirect costs), was estimated
to be € 6,815 per patient per year [12]. In a German study (2007–2009), outpatient physician
visits were the most expensive single cost category of the direct costs and indirect costs were
predominantly caused by productivity reduction at work [17].
Little is known about the cost-effectiveness and methodological quality of economic evalua-
tions of interventions for patients with MUS and FSS. Although helpful for policy makers, sys-
tematic reviews of cost-effectiveness data in this area are scarce. Earlier, Konnopka et al. [18]
published a systematic review of health economics studies for MUS. The aim of that systematic
review was to give an overview of both cost-of-illness studies and economic evaluations for
patients with MUS. Since in the review by Konnopka et al. [18] the quality of the included
studies was not addressed and the included studies were only up to 2008, we consider an
update is due.
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Therefore, the objectives of this review are to provide an overview of the evidence regarding
the cost-effectiveness of interventions for patients with MUS and FSS, and to assess the meth-
odological quality of the identified economic evaluations.
Methods
The methods and reporting of this systematic review are in concordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1 Table)
[19]. Prior to the start of article inclusion, we documented study methods in an international
prospective register of systematic reviews (PROSPERO) protocol (S1 Text), registration num-
ber CRD42017060424.
Literature search and study selection
We performed a literature search until 15 June 2018 in the following databases: PubMed, Psy-
cINFO, the National Health Service Economic Evaluation Database (NHS-EED), and the CEA
registry. The NHS-EED is a health economic database including economic evaluations. The
CEA registry includes studies in which a cost-effectiveness analysis was performed. In addition
to free-text terms, we used Medical Subject Headings (MeSH) terms and Psychological Index
Terms for searches within the PubMed and PsycINFO databases, respectively. In order to
identify economic evaluations on MUS, we selected key terms that were used in a Cochrane
review on non-pharmacological interventions for somatoform disorders and medically unex-
plained physical symptoms (MUPS) in adults [20] and combined these with health-economic
key terms. An information specialist was involved in the development of the search strategy. A
detailed description of the search strategy for every database can be found in the supplemen-
tary files (S1 Appendix). Additionally, we checked existing systematic reviews and the refer-
ences of studies included in our review manually for relevant studies.
We included studies on adult patients with MUS, reporting on psychological, physical/exer-
cise, internet-delivered, pharmacological and combined interventions compared with usual
care, waiting list, other physical or psychological treatment and describing health care use or
societal costs.
Only studies reporting on full economic evaluations were included, meaning that the stud-
ies compared both costs and effects of two or more conditions [21]. We excluded studies when
interventions focused on prevention or screening. We limited the scope of the studies to adult
patients with undifferentiated MUS and the three most common specific functional syn-
dromes FM, IBS and CFS. We excluded studies with medically (partly) explained symptoms or
medically unexplained symptoms as secondary diagnosis. The literature search was limited to
publications written in English, Dutch and German. We included both trial-based economic
evaluations (TBEEs) and model-based economic evaluations (MBEEs). In TBEEs costs and
effects are measured alongside an effectiveness trial, whereas in MBEEs available evidence is
synthesized and used to simulate (often long term) effectiveness and costs. We excluded study
protocols and included only original research.
Titles and abstracts of the search results were independently screened by two reviewers
(MSHW and JL). Studies that were in agreement with the inclusion criteria based on title and
abstract were retrieved as full text. Disagreements about the eligibility of studies were resolved
in a consensus meeting. A third reviewer (BV) was available in case of disagreement.
The full text articles were evaluated independently by the two reviewers (MSHW and JL) to
assess eligibility. In a consensus meeting the full text articles were discussed and discrepancies
between the two researchers were resolved by consensus, and when needed a third researcher
(BV) was consulted.
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Data extraction
Two reviewers (MSHW and JL) independently extracted data and assessed the methodological
quality of each study. The articles excluded on full-text level were documented and are pro-
vided in the supplementary files (S2 Table). The development of the data extraction form was
based on a previous review by one of the authors (JL) [22]. To pilot this data extraction form,
the reviewers screened the first eight articles together. After adaptation of the draft extraction
form, we extracted from each of the included articles the following information: name first
author, country, study design economic evaluation, target population, perspective, time hori-
zon, treatment alternatives (intervention, comparators and sample size), effect measurement
and valuation, discount rates, valuation year, costs categories, incremental costs, incremental
effects and health economic results.
Quality assessment
The methodological quality of the studies was assessed with the extended Consensus on Health
Economic Criteria (CHEC) list [23], which is recommended by the Cochrane Handbook for
Systematic Reviews of Interventions [24] for critical appraisal of the methodological quality of
health-economic evidence. The checklist contains 20 items covering the quality of the design
and reporting of the economic evaluation studies. Although the CHEC is not optimal for
assessing the methodological quality of MBEEs, we chose the CHEC for the quality assessment
of both TBEEs and MBEEs in order to optimize comparability of the results. Each question on
the CHEC checklist was scored with either ‘Yes’ (score 1), ‘Suboptimal’ (score 0.5), ‘No’ (score
0), ‘NA’ (not applicable) or ‘Uncertain’ (no score). The ‘Uncertain’ option was used only when
information on an item was not entirely clear. We did not contact authors when the published
information was insufficient to assign a score.
Prior to the quality assessment, to improve uniform scoring, two reviewers (MSHW and
JL) independently assessed and discussed eight included studies (two of each target population:
MUS, FM, IBS and CFS). A detailed description of the scoring instructions is provided in the
supplementary files (S2 Appendix). Two reviewers (MSHW and JL) assessed the quality of
each study independently. Disagreements between the two reviewers were resolved in a con-
sensus meeting.
Outcomes
For each study, we extracted the incremental costs, incremental effects and incremental
cost-effectiveness ratio (ICER), indicating the costs per additional quality-adjusted life
year (QALY) or any other (clinical) outcome. To enhance comparability of the health eco-
nomic results between studies conducted in different countries and at different years, ICERs
were converted to 2016 Euro using Purchasing Power Parity (PPP) rates [25] and the Con-
sumer Price Index [26]. To assess cost-effectiveness for studies reporting the cost per addi-
tional QALY, one year in perfect health, we applied an overall willingness-to-pay (WTP)
threshold of € 50,000 per QALY, a commonly used threshold in the Netherlands [27]. WTP
thresholds are not available for other outcome measures. The WTP threshold refers to the
maximum amount a country or society is willing to pay for a particular health gain [28].
When an ICER is below the WTP threshold, the intervention can be regarded as on average
cost-effective in comparison with the comparator. In accordance with the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS), we distinguished healthcare
and societal economic perspectives [29]. Due to heterogeneity, a meta-analysis could not be
conducted.
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Results
Literature search and study selection
In total, the search strategy yielded 1,713 articles. One study was found by additional reference
searching. After excluding 101 duplicates, the titles and abstracts of 1,613 articles were
screened for relevance. Title and abstract screening resulted in the exclusion of 1,535 articles,
mainly because they were not (full) economic evaluations or not primarily focused on MUS.
Of the 78 articles that were assessed full-text, 39 were excluded for being not full-economic
evaluations (n = 25), not primarily focused on MUS or FSS (n = 3), or not being original
research (n = 11). Finally, 39 articles were included for analysis. A flow diagram of the study
identification process is presented in Fig 1.
Data extraction
Overview of the included studies. The main characteristics of the included studies are pre-
sented in Table 1. The most recent study was published in July 2017 [30], and the oldest study
was published in 1992 [31]. Most studies were conducted in Europe (n = 30): UK (n = 11), the
Netherlands (n = 6), Germany (n = 3), Spain (n = 4), Sweden (n = 2), Denmark (n = 2), Scotland
(n = 1) and Norway, Sweden, Finland, Denmark (n = 1). The remaining studies (n = 9) were
conducted in the USA (n = 7), Mexico (n = 1) and one study had a global scope.
The majority (n = 30) of the studies were trial-based economic evaluations (TBEEs) of
which 24 originated from randomized trials. Nine economic evaluations were based on eco-
nomic modelling (MBEE).
In the included studies a societal perspective (n = 14) or a healthcare perspective (n = 15) or
both perspectives (n = 9) were used. One study did not explicitly report the study perspective
[32].
The time horizon was shorter than six months (n = 3) [33–35], between six months and
eight months (n = 6) [30, 36–40], between 14 months and two years (n = 7) [32, 41–46] or
three to 20 years (n = 5) [47–51]. The remaining studies had time horizons of one year (n = 18)
[31, 52–68].
Seven studies [34,35,42,47,49,52,53] reported funding by a pharmaceutical company.
Data on study population and treatment alternatives are presented in Table 2. Studies
focused on patients with undifferentiated MUS (n = 10) [31–33,41,46,48,54–57], on patients
with FM (n = 10) [30,36,37,42,47,52,53,58–60], on patients with IBS (n = 11) [34,35,43,49,50,
51,61–65], and on patients with CFS (n = 8) [38–40,44,45,66–68].
Studies focusing on MUS (n = 10) evaluated group training (n = 4): a collaborative group
intervention [54], cognitive-behavioral group training [46,48] and mindfulness-based cogni-
tive therapy [56]. The other studies [n = 6] evaluated individual psychodynamic interpersonal
therapy [55], (two-step) cognitive behavioral therapy [41,57], treatment by GPs [33] and a psy-
chiatric consultation letter [31,32]. These interventions were compared with enhanced medical
(usual) care [46,54–56], relaxation training [57], waiting list controls [41,48], or no interven-
tion [31–33].
Studies focusing on patients with FM (n = 10) compared a pharmacological intervention
with another pharmacological intervention (n = 4) [42,47,52,53], a group-based therapy
(n = 2), acceptance and commitment therapy (ACT) [30] and cognitive behavioral therapy
(CBT) [36] compared with a pharmacological intervention and treatment as usual or waiting
list. An educational intervention (n = 2) was compared with usual care or an educational dis-
cussion group [58,60] and an aquatic exercise program (n = 1) [37] or spa treatment (n = 1)
[59] was compared with usual care.
Cost-effectiveness of interventions for medically unexplained symptoms
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In studies focusing on IBS (n = 11), a pharmacological intervention (n = 3) was compared
with another pharmacological intervention or placebo [34,35,49], and internet-based cognitive
behavior therapy (n = 3) was compared with an internet chat forum, waiting list or pharmaco-
logical intervention [62–64] and other studies (n = 3) compared sacral nerve stimulation [51],
acupuncture [61], or a guidebook [65] with usual care. Psychotherapy (n = 1) was compared
Fig 1. Flow diagram of the study identification process.
https://doi.org/10.1371/journal.pone.0205278.g001
Cost-effectiveness of interventions for medically unexplained symptoms
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Table 1. Main characteristics of economic evaluations of interventions for MUS.
ID Authors (year) Country Economic
evaluation
Target
population
analysis Perspective Time
horizon
Industry
funding
1 Schro¨der et al, 2017 [46] Denmark TBEE MUS CUA/
CMA
Healthcare and
societal
16 months No
2 Konnopka et al, 2016
[54]
Germany TBEE MUS CUA Societal 1 year No
3 Visser et al, 2015 [48] Netherlands MBEE MUS CUA Healthcare and
societal
4 years No
4 Chernyak et al, 2014
[55]
Germany TBEE MUS CUA Healthcare 1 year No
5 Van Ravesteijn et al,
2013 [56]
Netherlands TBEE MUS CUA Healthcare and
societal
1 year No
6 Barsky et al, 2013 [57] United States TBEE MUS CEA Healthcare 1 year No
7 Hiller et al, 2003 [41] Germany TBEE MUS CEA Societal 2 years No
8 Morriss et al, 1998 [33] United Kingdom TBEE MUS CEA Healthcare 3 months No
9 Smith et al, 1995 [32] United States TBEE MUS CEA Not mentioned—
Healthcare
2 years No
10 Kashner et al, 1992 [31] United States TBEE MUS CEA Healthcare 1 year No
11 Luciano et al, 2017 [30] Spain TBEE FM CUA Healthcare and
societal
6 months No
12 Luciano et al, 2014 [36] Spain TBEE FM CUA Healthcare and
societal
6 months No
13 Luciano et al, 2013 [58] Spain TBEE FM CUA Healthcare and
societal
1 year No
14 Arreola Ornelas et al,
2012 [52]
Mexico MBEE FM CEA Healthcare 1 year Yes
15 Lloyd et al, 2012 [53] United States MBEE FM CEA Societal 1 year Yes
16 Beard et al, 2011 [42] United States MBEE FM CEA/
CUA
Healthcare and
societal
2 years Yes
17 Choy et al, 2010 [47] United Kingdom MBEE FM CEA/
CUA
Healthcare 3 years Yes
18 Gusi et al, 2008 [37] Spain TBEE FM CUA Healthcare and
societal
8 months No
19 Zijlstra et al, 2007 [59] Netherlands TBEE FM CUA Societal 1 year No
20 Goossens et al, 1996 [60] Netherlands TBEE FM CUA Societal 1 year No
21 Fisher et al, 2016 [49] Scotland MBEE IBS CUA Healthcare 5 years Yes
22 Tipsmark et al, 2016
[51]
Denmark MBEE IBS CUA Healthcare 20 years No
23 Huang et al, 2015 [34] United States MBEE IBS CEA/
CUA
Societal 12 weeks Yes
24 Stamuli et al, 2012 [61] United Kingdom TBEE IBS CUA Healthcare (NHS) 1 year No
25 Andersson et al, 2011
[62]
Sweden TBEE IBS CEA Societal 12 months No
26 Ljotsson et al, 2011 [63] Sweden TBEE IBS CEA Societal 1 year No
27 McCrone et al, 2008
[64]
United Kingdom TBEE IBS CEA Societal 1 year No
28 Bracco et al, 2007 [35] Norway, Sweden, Finland,
Denmark
TBEE IBS CUA Healthcare 12 weeks Yes
29 Robinson et al, 2006
[65]
United Kingdom TBEE IBS CEA Healthcare 1 year No
30 Spiegel et al, 2004 [50] Global scope MBEE IBS CEA Healthcare 10 years No
31 Creed et al, 2003 [43] United Kingdom TBEE IBS CEA Societal 15 months Unclear
(Continued)
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with a pharmacological intervention [43] and celiac sprue testing (n = 1) was compared with
empirical therapy [50].
In studies focusing on CFS (n = 8), a cognitive behavioral therapy (n = 6) [39,40,45,67,68]
was compared with usual care, adaptive pacing therapy, graded exercise therapy, specialist
medical care or counselling. Graded-exercise (n = 1) was compared with counseling or usual
care [38]. Pragmatic rehabilitation or multidisciplinary rehabilitation treatment (n = 2) was
compared with supportive listening, treatment as usual or CBT [44,66].
Effects, costs and uncertainty. Information on effect measurement and valuation is
described in Table 2. Seventeen studies included only a cost-effectiveness analysis (CEA), fif-
teen studies only a cost-utility analysis (CUA), seven studies included both a CEA and a CUA.
In studies with CEAs, outcomes were expressed as costs per unit improvement on a (clinical)
outcome measure. In studies with CUAs, outcomes were expressed as costs per QALY gained,
where the majority of the CUAs (n = 14) elicited utilities using the EuroQol 5D (EQ-5D).
TBEE studies (n = 30) included healthcare costs, patient and family costs including produc-
tivity losses (n = 15) [30,36,40,41,43–46,54,56,58,60,64,66,68]; direct treatment costs (n = 2)
[35,55], i.e. costs that are directly related to the intervention being studied; healthcare costs
(n = 6) [31–33,57,61,65] or intervention costs or work related costs and healthcare costs
(n = 7) [37–39,59,62,63,67].
Almost all TBEE studies described the method of measuring costs; in two studies [41,46] it
was unclear how costs were measured. In 13 TBEEs [31–33,36,37,41,55,57,58,60,62,63,67] it
was not clearly reported how costs were valued. In 13 TBEEs [30,35–37,40,43,44,54,55,58,61,
62,66] uncertainty was handled by means of bootstrapping and additional sensitivity analyses.
In 11 studies [38,39,45,46,56,59,60,63,64,67,68] bootstrapping without additional sensitivity
analyses or sensitivity analyses without bootstrapping were performed. In the remaining six
TBEEs [31–33,41,57,65] neither a bootstrapping procedure nor additional sensitivity analyses
were performed.
MBEE studies (n = 9) [34,42,47–53] included healthcare costs, patient and family costs
including productivity losses (n = 2) [34,53]; healthcare costs and work related costs (n = 2)
Table 1. (Continued)
ID Authors (year) Country Economic
evaluation
Target
population
analysis Perspective Time
horizon
Industry
funding
32 Vos-Vromans et al, 2017
[66]
Netherlands TBEE CFS CEA/
CUA
Societal 1 year No
33 Meng et al, 2014 [67] United States TBEE CFS CEA Societal 1 year No
34 Richardson et al, 2013
[44]
United Kingdom TBEE CFS CUA Healthcare 70 weeks No
35 McCrone et al, 2012
[68]
United Kingdom TBEE CFS CEA/
CUA
Healthcare and
societal
1 year No
36 Sabes-Figuera et al, 2012
[38]
United Kingdom TBEE CFS CEA Healthcare 6 months No
37 Severens et al, 2004 [45] Netherlands TBEE CFS CEA/
CUA
Healthcare 14 months No
38 McCrone et al, 2004
[39]
United Kingdom TBEE CFS CEA Societal 8 months No
39 Chisholm et al, 2001
[40]
United Kingdom TBEE CFS CEA Societal 6 months No
CEA: cost-effectiveness analysis, CUA: cost-utility analysis, MBEE: model-based economic evaluation, TBEE: trial-based economic evaluation, MUS: Medically
Unexplained Symptoms, FM: Fibromyalgia, IBS: Irritable Bowel Syndrome, CFS: Chronic Fatigue Syndrome.
https://doi.org/10.1371/journal.pone.0205278.t001
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Table 2. Characteristics of and results for economic evaluations of interventions for MUS.
ID
(ref)
Target population Treatment alternatives
(n)a
Effect
measurement and
valuationb
Discount
rates
Valuation
year
Costs categories Incremental costs
[95%CI](treatment
I vs treatment II and
for all costs unless
stated otherwise)
Incremental effects
[95%CI](treatment I
vs treatment II and for
all costs unless stated
otherwise)
Health economic
results
1
[46]
Patients (20–45) with
multiple functional
somatic symptoms for
at least 2 years within a
general hospital setting,
referred by their
primary care physician
I: Specialised Treatment
for Severe Bodily
Distress Syndromes
(group CBT program
(STreSS)) (54); II
enhanced usual care
(66)
QALYs (SF-6D)
and self-rated
physical health
No
discounting
applied
2010 Healthcare costs,
indirect costs and
public expenses
associated with
occupational status
and social benefits
Healthcare
perspective: -€1,004
[€-4,128; €2,120]
Societal perspective:
€940 [€−5,551;
€7,432]
QALY: 0.035 [0.00;
0.07] Self-rated
physical health: 20%
[0.4%; 39%]
Healthcare
perspective: STreSS
was on average
dominant for both
outcomes. Societal
perspective: The
ICERs were €26,988
per QALY and
€4,817 per patient
improved.
2
[54]
Patients with functional
somatic syndromes
I: Collaborative group
intervention (CGI)
(183); II: enhanced
medical care (EMC)
(145)
QALY (SF-6D) NA 2007 Healthcare costs
and productivity
losses
Societal perspective:
-€1,244. [CI NR]
QALY: 0.017 [CI NR] On average, CGI
dominated EMC.
3
[48]
Patients with a
diagnosis of
unexplained physical
symptoms according to
DSM-IV criteria
I: Cognitive behavioural
group training (CBGT)
(84); II: wait-list (WL)
(78)
QALYs (SF-36) 4% costs;
1.5% effects
2011 Healthcare costs
and work related
costs
Healthcare
perspective: €513 [CI
NR] Societal
perspective: -€886
[CI NR]
QALY: 0.06 [CI NR] Healthcare
perspective: ICER:
€8,738 per QALY
Societal perspective:
The group training
was dominant on
average.
4
[55]
Patients with
multisomatoform
disorder
I: Psychodynamic
interpersonal therapy
(PIT) (106); II:
enhanced medical care
(EMC) (102)
QALY (SF-6D) NA NR Treatment costs Healthcare
perspective: €784 [CI
NR]
QALY: 0.02 [-0.01;
0.05]
Healthcare
perspective: After
multiple imputation,
the ICER was
€46,194 per QALY.
5
[56]
Patients belonging to
the 10% most
frequently attending
patients in the
participating GPs,
fulfilling the DSM-IV
criteria of an
undifferentiated
somatoform disorder
I: Mindfulness-based
cognitive therapy (64);
II: Enhanced usual care
(61)
QALYs (SF-6D) NA 2010 Healthcare costs
and productivity
losses
Healthcare
perspective: €828 [CI
NR] Societal
perspective: €714;
[€-1,726; €3,237]
QALY: 0.012. [-0.019;
0.041]
Healthcare
perspective: ICER:
€72,782 per QALY
Societal perspective:
ICER: €62,034 per
QALY.
6
[57]
The highest 20%
outpatient utilizers
I: Two-step cognitive
behavioural therapy
accompanied by a
training seminar for
their primary care
physicians (CBT) (59);
II: relaxation training
(RT) (30)
Hypochondriasis
(Whiteley score);
NA NR Healthcare costs Healthcare
perspective: Not
reported for two
conditions
separately. For both
groups combined,
there is an average
cost reduction of
€522 in the year
preceding versus the
year following the
interventions.
Whiteley score not
reported separately for
both conditions.
Healthcare
perspective: ICER
not reported
7
[41]
Patients with medically
unexplained somatic
symptoms in a German
tertiary care facility
I: Cognitive
Behavioural treatment
program (SFD group)
(172); II: regular
treatment program
(123)
SOMS; WI;
CABAH; BDI;
DAQ
Costs 3% NR Healthcare costs
and productivity
losses. indirect
socioeconomics
costs
Societal perspective:
€-2,437 [CI NR]
No significant
differences between
conditions in terms of
development of
outcome measures
over time
Societal perspective:
ICER not reported
8
[33]
Patients with somatized
mental disorder in
Primary care
I: Treatment by GPs
having received
additional training for
somatized mental
disorder (103); II:
treatment by GPs
without additional
training (92)
Psychiatric
symptom
questionnaire
(GHQ-12)
NA 1995 Healthcare costs Healthcare
perspective:
-€10,464. [CI NR]
Percentage patients no
longer GHQ-12 cases:
13% [CI NR]
Healthcare
perspective: ICER
not reported
(Continued)
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Table 2. (Continued)
ID
(ref)
Target population Treatment alternatives
(n)a
Effect
measurement and
valuationb
Discount
rates
Valuation
year
Costs categories Incremental costs
[95%CI](treatment
I vs treatment II and
for all costs unless
stated otherwise)
Incremental effects
[95%CI](treatment I
vs treatment II and for
all costs unless stated
otherwise)
Health economic
results
9
[32]
Patients who somatize/
patients with 6 to 12
unexplained medical
symptoms
I: Patients’ physician
receives psychiatric
consultation letter (27);
II: patients’ physician
receive letter after a
year (one way cross-
over design) (29)
Health outcome
measured with
RAND Health
Status Measures
No 1990 Healthcare costs Healthcare
perspective: -€451
[€62; €724]
Physical functioning:
6.87. General health:
-2.23. Mental health:
-0.79. Social
functioning: -0.97
Healthcare
perspective: ICER
not reported
10
[31]
Patients with
somatization disorder
I: Psychiatric
consultation letter (40);
II: no psychiatric
consultation letter (33)
Mental Health;
General Health
Rating; Physical
Capacity
NA 1990 Healthcare costs Healthcare
perspective: -€710
[-€948. − €386]
Mental Health Index:
5.21 [-0.5; 10.9].
General Health Rating
Index: 4.18 [-1.3; 9.6].
Physical Capacity
Index: 15.15 [5.4, 24.9]
Healthcare
perspective: ICER
not reported.
11
[30]
Patients (18–65) with
FM recruited from
primary health care
centres
I: Group ACT (GACT)
(51); II: recommended
pharmacotherapy
(RPT) (52); III: waiting
list (53)
QALY (EQ-5D) NA 2014 Healthcare costs
and productivity
losses
Healthcare
perspective: I vs III;
€-1,642 [-2,533;
-751]; II vs III; €-745
[-1,751; 261]; I vs II;
€-897 [-1,559; -235].
Societal perspective:
I vs III €-1,875
[-2,930; -819]; II vs
III; €-1,481 [-2,626;
-338]; I vs II; €-394
[-1,226; 440].
QALY: I vs III: .05
[.04; .07]; II vs III: .04
[.02; .05]; I vs II: .01
[.00; .03].
Healthcare and
societal perspective: I
vs III: GACT on
average dominant II
vs III: RPT on
average dominant I
vs II: GACT on
average dominant
12
[36]
Patients with FM
recruited from primary
healthcare centres
I: Group-based
cognitive behavioural
therapy (CBT) (57); II:
Recommended
pharmacologic
treatment (RPT) (56);
III: Treatment as usual
(TAU) (55)
QALY (EQ-5D) NA 2011 Healthcare costs,
productivity losses
Healthcare
perspective: I vs III
€-1,748 [-2,938;
-558]; I vs II: €-1,931
[-2,983; -879]; II vs
III: 183 [-1,110;
1,477]. Societal
perspective: I vs III:
€-2,311 [-3,593;
-1,029]; I vs II: €
-2,467 [-3,561;
-1,373]; II vs III: 156
[-1,232; 1,544].
QALY: I vs III: 0.02
[-0.00; 0.03]; I vs II:
0.01 [-0.00; 0.03]; II vs
III: 0.00 [-0.01; 0.02].
Healthcare
perspective: CBT on
average dominant vs
RPT and TAU. ICER
for II vs III equals
€105,347 per QALY.
Societal perspective:
CBT on average
dominant vs RPT
and TAU. ICER for
II vs III equals
€84,625 per QALY
13
[58]
Primary care patients
meeting the American
College of
Rheumatology criteria
for FM
I: Psychoeducation
+usual care (108); II:
usual care (108)
QALYs (EQ-5D) NA 2008 Healthcare costs,
productivity losses
Healthcare
perspective: -€241
[-690; 323]; Societal
perspective: -€221
[-881; 444]
QALY: 0.12 [0.06;
0.19]
Healthcare and
societal perspective:
the intervention is
dominant on average
14
[52]
Patients with FM and
men and women with
musculoskeletal pain
I: Pregabalin; II:
Tramadol/
acetaminophen; III:
Duloxetine; IV:
Gabapentin; V:
Amitriptyline; VI:
Fluoxetine; VII:
Fluoxetine/
amitriptyline
Visual Analog Pain
Scale Score; Global
Improvement
(FIQ) of
Fibromyalgia
Costs and
effects at 5%
2010 Healthcare costs Healthcare
perspective: I vs V:
€11,291 [10,559;
12,024]; II vs V:
€12,052 [11,175;
12,929]; III vs V:
€18,431 [14,996;
21,867]; IV vs V:
€14,438 [12,630;
16,246]; VI vs V:
€1,063 [865; 1,261];
VII vs V € 1,700
[1,488; 1,911].
Reduction VAS
compared to V: I:
22.6% [21%,24%]; II:-
4.3% [-5%,-4%]; III:
12.0% [10%,14%];IV:
15.9% [14%,18%]; VI
-16.0% [-19%,-13%];
VII: -8.6% [-10%,-8%].
Reduction FIQ
compared to V: I:
16.4% [15%,17%]; II:
-1.5% [-1.5%,-1.3%];
III: 13.3% [10%,16%];
IV: 13.9% [12%,16%];
VI: -8.6% [-10%,-7%];
VII: 3.6% [3.2%,4%].
Healthcare
perspective: For VAS
outcomes, V
dominated II, VI and
VII on average. The
other arms had an
ICER of 49,906 (arm
I), 153,368 (arm III)
and 90,623 (arm IV).
For FIQ outcomes, V
dominated II, VI on
average. The other
arms had an ICER of
68,850 (arm I),
138,325 (arm III),
103,497 (arm IV) and
46,202 arm (VII).
(Continued)
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Table 2. (Continued)
ID
(ref)
Target population Treatment alternatives
(n)a
Effect
measurement and
valuationb
Discount
rates
Valuation
year
Costs categories Incremental costs
[95%CI](treatment
I vs treatment II and
for all costs unless
stated otherwise)
Incremental effects
[95%CI](treatment I
vs treatment II and for
all costs unless stated
otherwise)
Health economic
results
15
[53]
Patients with severe FM I: Pregabalin (150 or
225 mg); II: placebo; III:
duloxetine (60 or 120
mg; IV: gabapentin; V:
tramadol; VI:
milnacipran (100 or 200
mg); VII: amitriptyline
Response NA NR Healthcare costs
and productivity
losses
Societal perspective:
pregabalin (150 mg /
225 mg): vs II: €-741
/ -1,813; vs III
(60mg): €-407 /
-1,479; vs III
(120mg): €-851 /
-1,923; vs IV: €-208 /
-1,280; vs V: €490 /
-582; vs VI (100 mg):
€-762 / -1,834; vs VI
(200 mg): €-591 /
-1,663; vs VII: €1,029
/ -43
Pregabalin (150 mg /
225 mg): vs II: 59.58 /
62.21; vs III (60mg):
28.89 / 31.52; vs III
(120mg): 26.64 / 29.27;
vs IV: 29.13 / 31.75; vs
V: 9.20 / 11.83; vs VI
(100 mg): 47.07 /
49.69; vs VI (200 mg):
52.78 / 55.41; vs VII:
-10.61 / -7.98
Pregabalin (150 or
225 mg) dominates
II, III, IV and VI.
Pregabalin 250 mg
dominates V,
whereas the ICER of
pregabalin 250 mg vs
V equals €53 per
response. Compared
to VII, pregabalin
150 mg is being
dominated whereas
pregabalin 250 mg
results in €6 per
response.
16
[42]
Patients eligible for
pharmacotherapy who
had received a clinical
diagnosis of FM by
fulfilling 1990 ACR
classification criteria
I: first-line duloxetine;
II: second-line
duloxetine, III:
guideline-concordant
treatment sequence
symptom-control
months (SCM);
QALY (EQ-5D)
Costs and
effects at 3%
2009 Healthcare costs,
wider social
impacts (e.g.,
supportive care,
home adaptations,
and reduced
productivity)
Healthcare
perspective: I vs III:
€548 [CI NR]; II vs
III: €136 [CI NR].
Societal perspective:
NR
SCM: I vs III: 0.665
[CI NR]. II vs III:
0.460 [CI NR]. QALY:
I vs III: 0.0123 [CI NR]
II vs III: 0.0087 [CI
NR]
Healthcare
perspective: I vs III:
ICER is €44,754 per
QALY; €825 per
SCM; II vs III: ICER
is €15,587 per QALY;
€294 per SCM.
Societal perspective: I
vs III: ICER is
€42,336 per QALY;
€781 per SCM; II vs
III: ICER is €13,117
per QALY; €247 per
SCM
17
[47]
Patients with severe
FM, with FM meeting
ACR criteria
I: Pregabalin; II:
placebo; III: duloxetine;
IV: gabapentin; V:
tramadol; VI:
amitriptyline
Response / QALY
(SF-6D)
Costs and
effects at
3.5%
2008 Healthcare costs Healthcare
perspective:
pregabalin (300 mg /
450 mg): vs II: €891 /
905; vs III (60mg):
€377 / 391; vs III
(120mg): €252 / 266;
vs IV: €719 / 732; vs
V: €735 / 749; vs VI:
€880 / 895 [CI NR]
Response: pregabalin
(300 mg / 450 mg): vs
II: 3.40 / 3.55; vs III
(60mg): 1.65 / 1.80; vs
III (120mg): 1.52 / 1.67
vs IV: 1.66 / 1.81 vs V:
0.53 / 0.68 vs VI: -0.60
/ -0.45. QALY:
pregabalin (300 mg /
450 mg): vs II: 0.028 /
0.030; vs III (60mg):
0.014 / 0.015; vs III
(120mg): 0.013 / 0.014;
vs IV: 0.014 / 0.015; vs
V: 0.004 / 0.006; vs VI:
-0.005 / -0.004.[CI
NR]
QALY: I vs II: ICER
is €31,416 for 300 mg
and €30,558 for 450
mg. I vs III: ICER is
below €30,000 for all
different doses of
pregabalin versus
different doses of
duloxetine. I vs IV:
ICER is €51,834 for
300 mg and €48,464
for 450 mg. I vs V:
ICER is €167,787 for
300 mg and €132,999
for 450 mg. I vs VI:
Pregabalin (300 and
450 mg) is
dominated.
18
[37]
Women with FM
according to ACR
criteria
I: Aquatic exercise
program + usual care
(17); II: usual care (16)
QALY (EQ-5D) NA 2005 Healthcare costs
and time and travel
costs
Healthcare
perspective: €611 [CI
NR]. Societal
perspective: €1,220
[CI NR].
QALY: 0.131 [0.011;
0.290]
Healthcare
perspective: ICER:
€4,665 per QALY
[2,105; 55,545]
Societal perspective:
ICER: €9,310 per
QALY [4,206;
110,875].
19
[59]
Patients with primary
FM according to the
ACR 1990 classification
criteria
I: Spa treatment (SPA)
(58); II: usual care (UC)
(76)
QALY (SF-6D) NA 2000 Healthcare costs,
and direct and
indirect non-
healthcare costs
Societal perspective:
€1,894 [-793 to
4,218]
QALY: 0.00 [CI NR] ICER not reported
20
[60]
Patients meeting the
ACR criteria for FM
I: educational
discussion group (39);
II: Educational
cognitive intervention
(49); III: Waitlist
QALYc NA 1993 Direct healthcare
costs, direct non-
healthcare costs,
and productivity
losses
Societal perspective:
€2,303 [CI NR]
QALY: 0.027 [CI NR] ICER not reported
(Continued)
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Table 2. (Continued)
ID
(ref)
Target population Treatment alternatives
(n)a
Effect
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Discount
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Valuation
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Costs categories Incremental costs
[95%CI](treatment
I vs treatment II and
for all costs unless
stated otherwise)
Incremental effects
[95%CI](treatment I
vs treatment II and for
all costs unless stated
otherwise)
Health economic
results
21
[49]
Adults with moderate
to severe IBS with
constipation who have
previously received
antispasmodics and/or
laxatives
I: Linaclotide; II:
antidepressants
QALY (EQ-5D) 3.5% 2011/2012 Healthcare costs €809 [CI NR] QALY: 0.089 [CI NR] ICER:€9,045 per
QALY.
22
[51]
Patients with
diarrhoea-predominant
or mixed IBS according
to Rome III criteria
I: Sacral nerve
stimulation (SNS) (26);
II: no-treatment (17)
QALY
(transformed using
GSRS-IBS scores)
(EQ-5D)
Costs and
effects at 3%
2013 Healthcare costs Healthcare
perspective: €5,949
[4,021; 7,876] at
4-year and €2,897
[2,396; 3,396] at
20-year
QALY: 0.163 [0.146;
0.180] at 4 years; 0.131
[0.1186; 0.1434] at 20
years
ICER: €36,582 per
QALY after 4 years;
€22,112 per QALY
after 20 years.
23
[34]
Adult patients with IBS
with constipation
I: Linaclotide; II:
Lubiprostone
QALY (EQ-5D) /
Response
(IBS-QoL)
NA NR Healthcare costs
and productivity
losses
Healthcare
perspective: - €88–-
€65. Societal
perspective: NR
QALY: 0.0004–0.0014.
Response: 4.6% - 6.3%
ICER: Linaclotide
dominated
Lubiprostone on
average.
24
[61]
Patients with IBS I: Acupuncture as
adjunct to usual care
(116) II: Usual care
(117)
QALY (EQ-5D) NA 2010 Healthcare costs Healthcare
perspective:€291
[-73; 656]
QALY: 0.0035
[-0.0389; 0.0458]
ICER: €83,160 per
QALY.
25
[62]
People diagnosed with
IBS by a physician and
presently fulfilling the
ROM III criteria for
IBS
I: Internet-based
cognitive behaviour
therapy (43); II:
Internet chat forum
(43)
GSRS-IBS NA 2008 Direct medical
costs and direct
and indirect non-
medical costs
Societal perspective:
-€5,437 [CI NR]
Fraction of recovered
participants on
GSRS-IBS: 0.34 [CI
NR]
ICER: €-15,992 (cost
saving) per clinically
significant
improvement
26
[63]
Patients fulfilling the
ROME III criteria for
IBS
I: Internet-based
cognitive behaviour
therapy (30); II: waiting
list (31)
GSRS-IBS NA 2010 Direct medical
costs and direct
and indirect non-
medical costs
Societal perspective:
-€5,210 [CI NR]
Fraction of recovered
participants on
GSRS-IBS: 0.14 [CI
NR]
ICER: €-37,216 (cost
saving) per clinically
significant
improvement
27
[64]
Patients aged 16–50
years with a clinical
diagnosis of IBS
I: CBT + Mebeverine
(72); II: Mebeverine
(76)
Irritable bowel
severity scoring
system
NA 2000/2001 healthcare costs
and productivity
losses
Societal perspective:
€515 [CI NR]
Clinically significant
change in severity:0.1
[CI NR]
ICER: €5,149 per
clinically significant
change in IBS
severity
28
[35]
Non-diarrhoea IBS
patients
I: Tegaserod (247); II:
placebo (238)
QALY (EQ-5D) NA NR Treatment costs Healthcare
perspective: €173 [CI
NR]
QALY: 0.0077 [CI NR] ICER:€22,454 per
QALY
29
[65]
Patients with IBS 18
years and older
I: Guidebook (141); II:
guidebook and self-help
group session (139); III:
usual care (140)
Patients’ clinical
global impression
scores
NA Unclear Healthcare costs Healthcare
perspective: I and II
vs III: -€116 [-€163
to -€68]
Perceived symptom
severity: I vs II vs III:
0.51 [0.23; 0.79).
ICER: not reported
30
[50]
Patients fulfilling the
ROME II criteria for
IBS-D
I: Serologic test for CS
followed by endoscopic
biopsy for positive tests;
II: Empirical IBS
treatment
symptomatic
improvement
Costs and
effects at 3%
NR
(clearly)
Healthcare costs Healthcare
perspective: €86 [CI
NR]
Symptomatic
improvement: -0.07%
[CI NR]
ICER: €12,311 per
symptomatic
improvement.
31
[43]
Patients with severe
and very severe
symptoms of IBS, at
least 6 months and not
responding to "usual"
medical treatment
I: Psychotherapy (85);
II: paroxetine (86); III:
treatment as usual (86)
Abdominal pain,
SF-36
Costs 6% 1997/1998 Healthcare costs,
direct non-health
care costs and
productivity losses
Healthcare
perspective: I vs III:
-€591 [CI NR];II vs
III: -€404 [CI NR].
Societal perspective:
Not reported
SF-36 physical
component: I vs III:
5.6 [CI NR]; II vs III:
5.9 {CI NR]. Pain: I vs
III: 0.6 [CI NR]; II vs
III: -0.7 [CI NR]
ICER: not reported
32
[66]
Patients (18–60) with
CFS diagnosed and
referred to a
rehabilitation centre
I: Multidisciplinary
rehabilitation treatment
(MRT) (57); II:
Cognitive behavioural
therapy (CBT) (52)
QALY (EQ-5D),
fatigue severity
(CIS).
NA 2012 Healthcare costs,
patient and family
costs, productivity
losses
Societal perspective:
€5,629 [2,599; 8,452]
QALY: 0.09 [-0.02;
0.19] CIS: -6.48
[-11.54, -1.42]
ICER: €856 per unit
of the CIS fatigue
subscale. QALY:
€118,074 per QALY
33
[67]
Patients aged 18–65
years with at least six
months of persistent
fatigue
I: Cognitive behavioural
therapy based fatigue
self-management
(FSM) (37); II: usual
care (36)
Fatigue Severity
Scale (FSS)
NA 2010 Direct healthcare
costs; direct non-
healthcare costs,
indirect costs
Societal perspective:
-€1.615 [-4,790 to
1,023]
FSS reduction: 0.73
[0.15; 1.42]
ICER:-€2,203 per
FSS gain, indicating
that FSS dominates
on average.
(Continued)
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34
[44]
Patients with CFS/ME
diagnosed using the
Oxford criteria
I: pragmatic
rehabilitation (PR) (95);
II: supportive listening
(SL) (101); III:
treatment as usual
(TAU) (100)
QALY (EQ-5D) Costs and
effects at
3.5%
2008/2009 Healthcare costs
and productivity
losses
Healthcare
perspective: I vs III:
€289 [€-628; 1,207];
II vs III: €609 [€-331;
1,549].
QALY: I vs III: -0.012
[-0.088; 0.065] II vs III:
-0.042 [-0.122; 0.038]
On average, TAU
dominates PR and SL
35
[68]
Patients with the
Oxford diagnostic
criteria for CFS
I: Adaptive Pacing
Therapy (APT) (159);
II: Cognitive Behaviour
Therapy (CBT) (161);
III: Graded Exercise
Therapy (GET) (160);
IV: Specialist Medical
Care (SMC) (160)
Chalder Fatigue
Scale; SF-36
physical function
sub-scale; QALY
(EQ-5D)
NA 2009/2010 Healthcare costs
and productivity
losses
Healthcare
perspective: I vs IV:
€1,096; II vs IV:
€1,204; III vs IV:
€1,079. Societal
perspective: I vs IV:
€2,522; II vs IV:
-€930; III vs IV:
-€629
QALY: I vs IV: 0.0149;
II vs IV: 0.0492; III vs
IV: 0.0343. Fatigue: I
vs IV: 1.9; II vs IV:
11.1; III vs IV: 14.0.
Disability: I vs IV: -8.5;
II vs IV: 13.4; III vs IV:
12.6.
ICER: From a
healthcare
perspective, cost per
QALY was €24,475
for CBT, €31,456 for
GET and €73,576 for
APT. From a societal
perspective, CBT and
GET dominated
SMC on average,
whereas SMC was
preferred over APT
for all outcomes.
36
[38]
Patients from GP
practices who had
experienced symptoms
of fatigue for at least
three months
I: Graded-exercise (71);
II: counselling (76); III:
usual care plus a self-
help booklet (75)
Chalder Fatigue
Scale
NA 2006/2007 Healthcare costs
and social care
costs
Healthcare
perspective: I vs III:
€364 [197; 533]; II vs
III: €590 [402; 780];
Chalder
improvements: I vs III:
1.1 [-2.3; 4.4]; II vs III:
-0.1 [-3.1; 2.9]
ICER: I vs III: €1,377
per unit of clinically
significant
improvement on the
Chalder Fatigue
Scale. II vs III:
Counselling is
dominated by usual
care plus self-help
booklet
37
[45]
Patients, aged 18–60,
with CFS
I: Cognitive behaviour
therapy (CBT) (92); II:
guided support groups
(SG) (90); III: natural
course (88)
QALY (EQ-5D),
Response
No dis-
counting
1998 Healthcare costs
and productivity
losses
Healthcare
perspective: I vs III:
€1,440; II vs III:
€1,528. Societal
perspective: I vs III:
-€1,164; II vs III:
-€8,519
QALY: I vs III: 0.0279;
II vs III: -0.0476.
Response: I vs III: 7%;
II vs III: -9%.
ICER: I vs III:
€28,674 per clinically
significant
improvement and
€29,875 per QALY; I
vs II: CBT dominated
SG on average
38
[39]
Patients with
unexplained fatigue
that had lasted for more
than 3 months
I: Cognitive behavioural
therapy (52); II: graded
exercise therapy (50);
III: usual care plus a
self-help booklet (30)
Chalder fatigue
score
NA 2000/2001 Healthcare costs,
social services,
informal care
I and II combined vs
III: €232 [CI NR]
Chalder fatigue score:
I and II combined vs
III: 4.38
ICER: not reported
39
[40]
Patients from GP
practices who had
experienced symptoms
of fatigue for at least
three months
I: Counselling (65); II:
cognitive behaviour
therapy (64)
Fatigue
Questionnaire
NA 1998 Healthcare costs,
informal care and
productivity losses
Societal perspective:
-€316 [-1938; 1,701].
Fatique score: 0.90
[-1.80; 3.60]
ICER: not reported
ACR: American College of Rheumatology; ANTI: anticonvulsant; BDI: Beck Depression Inventory; BID: twice a day; BPI: Brief Pain Inventory; CABAH: Cognitions
About Body and Health Questionnaire; CFS: chronic fatigue syndrome; CI: confidence interval; CI NR: confidence interval not reported; CIS: Checklist Individual
Strength; CS: celiac sprue; DAQ: Dysfunctional Analysis Questionnaire; DUL: duloxetine; FIQ: Fibromyalgia Impact Questionnaire; FM: fibromyalgia; GHQ-12:
12-item General Health Questionnaire; GSRS-IBS: Gastrointestinal Symptom rating scale-IBS; HRQoL: health related quality of life; IBS: irritable bowel syndrome;
ICER: Incremental Cost-Effectiveness Ratio; LOCF: last observation carried forward; MUS: medically unexplained symptoms; NA: not applicable; NR: not reported;
PRAM: pramipexole; QALY: quality-adjusted life year; SF-36: Short Form-36; SNRI: Serotonin–norepinephrine reuptake inhibitor; SOMS; Screening for Somatoform
Symptoms; TCA: tricyclic antidepressant; TRAM: tramadol; WI: Whiteley Index; WtP: Willingness to Pay.
a Sample size (n) of the intervention conditions applicable only to trial-based economic evaluations.
b Valuation method of utilities applicable only to cost-utility analyses.
c Valuation method unclear.
Only outcomes as reported in main/base case analyses.
https://doi.org/10.1371/journal.pone.0205278.t002
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[42,48] and healthcare costs (n = 5) [47,49–52] The cost sources were reported in seven
MBEEs [34,47–50,52,53]. Both probabilistic and deterministic sensitivity analyses were con-
ducted in six MBEEs [34,48–52], whereas in three MBEEs [42,47,53] either a probabilistic or a
deterministic sensitivity analysis was conducted.
Quality assessment
Tables 3 and 4 describe the CHEC quality scores per item. None of the included studies met all
CHEC criteria. Two items, discussing the generalizability of the results (item 18) and ethical
and distributional issues (item 20), had the lowest scores. Three studies discussed the gener-
alizability of the study results properly [43,47,50], whereas in the remaining studies the gener-
alizability of results only was mentioned but not discussed (n = 10) [30,36,37,41,46,54,58,63,
66,67] or not described at all (n = 26). On average, the items on well-defined research question
(item 3), appropriateness of the economic study designs (item 4) and identified important and
relevant outcomes (item 11) had the highest scores. One study [65] defined the research ques-
tion incomplete, for all 39 studies the economic study design was considered appropriate.
Outcomes
The incremental costs, incremental effects and health economic results in terms of ICERs
of the reference-cases are presented in Table 2. Twenty-two (five of which on MUS
[46,48,54,55,56]; eight on FM [30,36,37,42,47,58,59,60], five on IBS [34,35,49,51,61], four
on CFS [44,45,66,68]) out of 39 studies included a CUA with QALYs as outcome. ICERs
were reported in 24 studies and in 13 of these studies interventions [30,34,36,37,42,46,47,
48,49,51,54,58,68] were dominant over the control condition. Group interventions focusing
on MUS (n = 3)[46,48,54] or FM (n = 4) [30,36,37,58] might be more cost-effective in com-
parison with individual interventions. Four pharmacological interventions focusing on
FM (n = 2) [42,47] or IBS (n = 2) [34,49] and two individual interventions focusing on IBS
(n = 1) [51] or CFS (n = 1) [68] appeared to be cost-effective in comparison with the control
condition.
Medically unexplained symptoms. In studies focusing on MUS, four studies assessed the
cost-effectiveness of group interventions [46,48,54,56] and one study an individual interven-
tion [55]. The group interventions, group CBT program (STreSS) [46], collaborative group
intervention [54], and cognitive-behavioural group training [48] appeared to be cost-effective,
but the mindfulness-based cognitive group therapy [56] was not cost-effective. The individu-
ally administered psychodynamic interpersonal therapy [55] was not cost-effective either.
Each of these interventions was compared to enhanced usual care or enhanced medical care,
except for the use of a wait-list condition in Visser et al.[48].
Fibromyalgia. In the studies focusing on FM, the aquatic exercise program [37] appeared
to be cost-effective whereas spa treatment [59] was not cost-effective; both group interventions
were compared to usual care. Three other studies on group-based cognitive behavioral therapy
(CBT) [36], additional psychoeducation[58] or group based acceptance and commitment ther-
apy (ACT) [30] were cost-effective compared to recommended pharmacologic treatment or
treatment as usual or waiting list or usual care. In an older study [60] educational cognitive
intervention was not cost-effective in comparison with an educational discussion group. In
two studies, both funded by the pharmaceutical industry, a pharmacological intervention was
compared with another pharmacological intervention. Duloxetine as second-line treatment
was cost-effective [42] and pregabalin 450 mg appeared to be cost-effective in comparison
with duloxetine 120 mg, but pregabalin 450 mg was not cost-effective compared to tramadol,
amitriptyline or placebo [47].
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Irritable bowel syndrome. Three studies focused on IBS [34,35,49], all funded by the
pharmaceutical industry, compared a pharmacological intervention with another pharmaco-
logical intervention or placebo. Linaclotide appeared to be more cost-effective in comparison
with antidepressants [49] and with lubiprostone [34]. Tegaserod [35] did not appear to be
more cost-effective than placebo. Sacral nerve stimulation, a non-pharmacological interven-
tion [51], appeared to be cost-effective in comparison with no treatment. Another non-phar-
macological intervention, acupuncture as adjunct to usual care [61], was not cost-effective in
comparison with usual care.
Chronic fatigue syndrome. In studies including patients with CFS, the interventions
pragmatic rehabilitation and supportive listening appeared to be not cost-effective compared
Table 3. Quality assessment CHEC-extended.
Item Study ID
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
1.Is the study population clearly described? 0.5 0.5 1 0.5 0.5 1 1 1 1 0.5 1 1 1 0 0.5 0.5 1 1 1 0.5 0.5
2.Are competing alternatives clearly described? 1 1 1 1 1 1 1 1 1 0 1 1 1 0.5 0.5 0.5 0.5 1 1 1 0.5
3.Is a well-defined research question posed in
answerable form?
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
4.Is the economic study design appropriate to the
stated objective?
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.Are the structural assumptions and the validation
methods of the model properly reported (models
only)?
NA NA 0 NA NA NA NA NA NA NA NA NA NA 0.5 0.5 1 0.5 NA NA NA 0
6.Is the chosen time horizon appropriate in order to
include relevant costs and consequences?
1 1 1 1 1 1 1 0 1 1 0.5 0.5 1 1 1 1 1 0.5 1 1 1
7.Is the actual perspective chosen appropriate? 1 1 1 0.5 1 0 1 0 0 0 1 1 1 0.5 1 1 0.5 1 1 1 0.5
8.Are all important and relevant costs for each
alternative identified?
1 1 1 0 1 0.5 1 1 1 1 1 1 1 1 1 0 0.5 0.5 1 1 1
9.Are all costs measured appropriately in physical
units?
0 1 1 1 1 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1
10.Are costs valued appropriately? 0.5 0.5 1 0 1 0 0 0 0 0 0.5 0 0 0 0 0 X 0 1 0 1
11.Are all important and relevant outcomes for each
alternative identified?
1 1 1 1 1 1 1 1 0.5 1 1 1 1 1 1 1 1 1 1 1 1
12.Are all outcomes measured appropriately? 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
13.Are outcomes valued appropriately? 1 1 1 1 1 NA NA NA NA NA 1 1 1 NA NA 1 1 1 1 0 1
14.Is an appropriate incremental analysis of costs
and outcomes of alternatives performed?
1 1 1 1 1 0 0 1 0 0 1 1 1 1 1 1 1 1 1 0 1
15.Are all future costs and outcomes discounted
appropriately?
0 NA 1 NA NA NA 0.5 NA 0 NA NA NA NA 1 NA 1 1 NA NA NA 1
16.Are all important variables, whose values are
uncertain, appropriately subjected to sensitivity
analysis?
0.5 1 1 1 0.5 0 0 0 0 0 1 1 1 1 0.5 0.5 0.5 1 0.5 0.5 1
17.Do the conclusions follow from the data
reported?
1 1 0.5 0.5 1 1 1 0.5 1 1 1 0.5 1 0.5 0.5 0.5 0 1 0.5 1 1
18.Does the study discuss the generalizability of the
results to other settings and patient/client groups?
0.5 0.5 0 0 0 0 0.5 0 0 0 0.5 0.5 0.5 0 0 0 1 0.5 0 0 0
19.Does the article/ report indicate that there is no
potential conflict of interest of study researcher(s)
and funder(s)?
1 1 0.5 1 1 1 0 0 0 1 1 1 1 0 1 1 1 1 1 0 1
20.Are ethical and distributional issues discussed
appropriately?
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0: no, 0.5: suboptimal, 1: yes, X: unclear, NA: not applicable
https://doi.org/10.1371/journal.pone.0205278.t003
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to treatment as usual [44]. On average, individual cognitive behavior therapy (CBT) was more
cost-effective in comparison with specialist medical care [68]. In another study [45] CBT was
compared with guided support groups (SG) and the natural course. CBT was less costly and
more effective than SG and even cost-effective in comparison with the natural course of the
disease. Compared to CBT, multidisciplinary rehabilitation treatment [66] appeared not to be
cost-effective.
Discussion
Main findings
To our knowledge, this is the first systematic review of cost-effectiveness of interventions for
undifferentiated MUS and the three most well-known functional syndromes FM, IBS and CFS
with a methodological quality assessment of the included studies. We identified 39 full eco-
nomic evaluations of interventions for treating patients with MUS and FSS. Heterogeneity of
the included studies concerning interventions, time horizon, and outcome was high. Twenty-
two out of 39 studies included a CUA with QALYs as outcome. In 13 CUAs the intervention
conditions dominated the control conditions or had an ICER below the WTP threshold of €
Table 4. Quality assessment CHEC-extended (studies 22–39) continued.
Item Study ID
22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
1.Is the study population clearly described? 0.5 0 0 1 1 1 0 1 1 1 1 1 0.5 0.5 0.5 1 0.5 0.5
2.Are competing alternatives clearly described? 1 0.5 0.5 1 1 1 0.5 1 0.5 1 1 1 1 1 1 1 1 0
3.Is a well-defined research question posed in answerable form? 1 1 1 1 1 1 1 0.5 1 1 1 1 1 1 1 1 1 1
4.Is the economic study design appropriate to the stated objective? 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
5.Are the structural assumptions and the validation methods of the
model properly reported (models only)?
0 0.5 NA NA NA NA NA NA 1 NA NA NA NA NA NA NA NA NA
6.Is the chosen time horizon appropriate in order to include
relevant costs and consequences?
1 0 1 1 1 1 0 1 1 1 1 1 1 1 0.5 1 0.5 0.5
7.Is the actual perspective chosen appropriate? 0 1 0.5 1 1 1 0 0.5 0 0.5 1 1 0.5 1 0.5 1 0.5 1
8.Are all important and relevant costs for each alternative
identified?
0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1
9.Are all costs measured appropriately in physical units? 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1
10.Are costs valued appropriately? 0.5 0 1 0 0 1 1 0.5 0 0.5 1 0 1 1 1 1 1 1
11.Are all important and relevant outcomes for each alternative
identified?
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
12.Are all outcomes measured appropriately? 0 0.5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
13.Are outcomes valued appropriately? 1 1 1 NA NA NA 1 NA NA NA 1 NA 1 1 NA 1 NA NA
14.Is an appropriate incremental analysis of costs and outcomes of
alternatives performed?
1 0 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 0
15.Are all future costs and outcomes discounted appropriately? 1 NA NA NA NA NA NA NA 1 0.5 NA NA 1 NA NA 0 NA NA
16.Are all important variables, whose values are uncertain,
appropriately subjected to sensitivity analysis?
1 1 1 1 0.5 0.5 1 0 1 1 1 0.5 1 0.5 0.5 0.5 0.5 1
17.Do the conclusions follow from the data reported? 0.5 1 1 1 1 0 1 1 0.5 1 1 1 1 1 1 1 1 1
18.Does the study discuss the generalizability of the results to other
settings and patient/client groups?
0 0 0 0 0.5 0 0 0 1 1 0.5 0.5 0 0 0 0 0 0
19.Does the article/ report indicate that there is no potential
conflict of interest of study researcher(s) and funder(s)?
1 0.5 0.5 1 1 1 0.5 1 0 0.5 1 1 1 1 1 0 0 0
20.Are ethical and distributional issues discussed appropriately? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0: no, 0.5: suboptimal, 1: yes, X: unclear, NA: not applicable.
https://doi.org/10.1371/journal.pone.0205278.t004
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50,000 per QALY, meaning that the interventions were (on average) cost-effective in compari-
son with the control conditions. In nine CUAs the intervention condition was not cost-effec-
tive compared with the control conditions. Group interventions focusing on MUS (n = 3) or
FM (n = 4) might be more cost-effective than individual interventions.
Discussion of the results
Although this study provides valuable information regarding existing evidence on the cost-
effectiveness of interventions for MUS, the comparability of the studies included in this sys-
tematic review was limited due to heterogeneity in terms of interventions, (economic) study
design, time horizon and outcome measures. The variety in effect measures used in the eco-
nomic evaluations limits the comparability of the studies and their results. Only twenty-two
studies used both clinical effects and QALYs as outcome. The other studies included CEAs
using diagnosis-specific measures. The variety in outcome measures amongst these studies
was high.
A general limitation of the included studies is that the costs of somatic specialist care were
often not taken into account, while it can be expected that proper treatment of MUS can lead
to a decrease in these costs. This could potentially result in underestimation of the cost-effec-
tiveness of the interventions.
The studies included in this systematic review contained four studies [31–33,41] that were
also part of an earlier systematic review on the cost-of-illness and economic evaluations of
interventions for MUS disorders by Konnopka et al.[18]. In that systematic review, 13 studies
were included with patients with MUS, five cost-of-illness studies and eight economic evalua-
tions, of which only two cost-effective analyses. Similar to our review the comparability of
included studies was limited due to the heterogeneity concerning design, methods and year of
study conduct.
An intervention may be cost-effective only after a longer period of time. One study [48] did
show through a modeling approach that cognitive behavioral group intervention could be
cost-effective after 21 months. The time horizon of only 12 months used in many studies may
be the reason that interventions were not cost-effective. An important advantage of MBEEs is
that they allow cost-effectiveness to be modelled over longer periods, although at the cost of
more uncertainty. Six out of nine included MBEEs had a time horizon of at least two years.
Quality assessment. Due to the variability of the study methodological quality, drawing
conclusions regarding the cost-effectiveness of different types of interventions focusing on dif-
ferent target populations is difficult. Assessing the methodological quality of the studies using
the CHEC-list [23], a validated checklist for the methodological quality assessment of eco-
nomic evaluations, is partly subjective and we have limited ourselves to discuss all items sepa-
rately. To enhance the reliability we applied the procedure as mentioned in the methods
paragraph. Moreover, the separate items of the CHEC-list were valued equally and the overall
quality score therefore does not reflect that certain items, such as the chosen time horizon and
the chosen perspective, could be perceived as having a relatively large impact on study meth-
odological quality. In the included studies the chosen time horizon was usually appropriate
and the chosen perspective depended on the healthcare system of the country of the study.
Strengths and limitations
This review has several strengths. We used a broad search strategy in which psychological,
medical and health economic literature databases were searched thoroughly. We included all
health economic studies focusing on interventions for MUS with the three most prevalent FSS.
Furthermore, the quality of the included studies was appraised with the CHEC [23].
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Additionally, we applied the recommended strategy for conducting and reporting systematic
reviews [19]. In this review we only presented base case results and not the results of sensitivity
analyses. Therefore decision makers should consider context-specific factors (e.g. cost-reim-
bursement of interventions) when deciding on implementing interventions.
This study also has some limitations. The literature search had language restrictions (only
English, German, and Dutch), but we assume that economic evaluations will be published
mainly in international journals. The included patient groups vary in terms of reported sever-
ity, i.e. number and duration of symptoms, functional disability or quality of life. This might
constitute a limitation in terms of how MUS are defined but also whether the patients have
similar characteristics at inclusion in terms of, e.g. length of illness before treatment, severity
of symptoms or previous treatments. Cost-effectiveness of different interventions is not only
supposed to depend on the intervention itself, but also on underlying medical (and demo-
graphic) conditions and prognostic factors such as number of symptoms, number of body sys-
tems involved and number of times symptoms are presented. [10].
With regard to the interventions, it should be noted that the availability of the pharmaco-
therapy and non-pharmacological interventions can differ per country.
Another limitation is the methodological quality assessment with the CHEC. The CHEC
list [23] is the best available instrument for the quality assessment of economic evaluations,
and is recommended by the Cochrane Handbook for Systematic Reviews of Interventions [24]
for critical appraisal of the methodological quality of health-economic evidence. The presented
descriptive information and quality assessment gives a broad picture of the study designs and
study quality, but the information is incomplete and decision makers should look in detail at
the studies of interest, especially so for the model-based economic evaluations, for which the
CHEC-list is less appropriate as a quality assessment tool.
As all included studies were conducted in Western countries, the generalizability of the
results is presumably limited due to differences in healthcare provision of a country.
Recommendations
This systematic review provides an overview of group interventions and individual interven-
tions for patients with MUS. Further research is needed to investigate the willingness to partic-
ipate in group interventions. To address the disease burden and societal costs associated with
MUS, it is important to know the cost-effectiveness of available interventions. While the cur-
rent review shows that not all interventions are cost-effective, this could also be the result of
choices made in the included studies such as a relatively short time horizon and the chosen
perspective. Due to the chronic nature of MUS and the societal costs MUS may cause outside
of the healthcare domain (e.g. lost productivity), it is recommended to conduct high quality
economic evaluations of interventions for patients with MUS, with a long time horizon and a
chosen perspective in line with the national or local guidelines and the decision makers’ infor-
mation requirements. The studies would ideally use both perspectives, healthcare and societal
perspective, so that the outcomes become more relevant for decision makers in different set-
tings. High quality economic evaluations are necessary in order to draw robust conclusions
about the cost-effectiveness of interventions for MUS.
Conclusion
The current review provides an overview of 39 studies of interventions for patients with
MUS, FM, IBS and CFS and the methodological quality assessment of these studies. In 13 out
of 22 studies the intervention condition dominated the control conditions, meaning that the
interventions were (on average) cost-effective in comparison with the control conditions.
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Considering the limited comparability due to the heterogeneity of the studies, the group inter-
ventions might be more cost-effective than individual interventions.
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